Tue. 27 Feb 2024, 12:27pm ET
Benzinga
Earnings, News
Tarsus Pharmaceuticals (NASDAQ:TARS) reported quarterly losses of $(1.31) per share which beat the analyst consensus estimate of $(1.36) by 3.68 percent. This is a 167.35 percent decrease over losses of $(0.49) per share from the same period last year. The company reported quarterly sales of $13.08 million which beat the analyst consensus estimate of $5.66 million by 131.02 percent. This is a 30.76 percent increase over sales of $10.00 million the same period last year.